Key terms

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest JAZZ news

Yesterday 8:29am ET Stifel Nicolaus Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ) Yesterday 7:59am ET Truist Financial Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ) Yesterday 6:35am ET RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ) Yesterday 6:31am ET Optimistic Outlook for Jazz Pharmaceuticals Despite Q1 Challenges Yesterday 6:09am ET Buy Rating Affirmed: Jazz Pharmaceuticals’ Resilient Base and Promising Pipeline Drive Positive Outlook May 01 3:55am ET Barclays Remains a Buy on Jazz Pharmaceuticals (JAZZ) Apr 30 4:14pm ET Baird starts Praxis Precision at Outperform on ulixacaltamide’s potential Apr 23 5:59am ET Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays Apr 08 10:00pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ) Apr 02 7:34am ET Jazz completes rolling submission of BLA for zanidatamab antibody Mar 24 9:50pm ET Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR) Mar 21 2:20am ET Optimistic Outlook on Jazz Pharmaceuticals’ Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis Mar 20 7:21am ET Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ) Mar 20 7:17am ET Truist Financial Remains a Buy on Jazz Pharmaceuticals (JAZZ) Mar 20 6:58am ET Jazz Pharmaceuticals price target raised to $188 from $171 at Piper Sandler Mar 20 6:45am ET Buy Rating Affirmed for Jazz Pharmaceuticals on Strong Zanidatamab Revenue Prospects and Clinical Milestones Mar 20 6:10am ET Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ) Mar 20 5:10am ET Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Shockwave Medical (SWAV) and Healthequity (HQY) Mar 15 9:22am ET Jazz Pharmaceuticals price target raised to $230 from $225 at Stifel Mar 14 6:20am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH) Mar 12 6:25am ET Zymeworks price target raised to $14 from $12 at Wells Fargo Mar 07 7:15am ET TD Cowen Remains a Buy on Jazz Pharmaceuticals (JAZZ) Mar 05 8:30am ET Avadel Pharmaceuticals price target raised to $22 from $20 at Needham Mar 05 8:28am ET Avadel Pharmaceuticals price target raised to $22 from $20 at Craig-Hallum Mar 05 7:41am ET Avadel Pharmaceuticals price target raised to $29 from $27 at Oppenheimer Mar 04 3:41pm ET Avadel Pharmaceuticals ‘pleased’ with ruling in patent litigation with Jazz Pharmaceuticals Mar 04 3:12pm ET Avadel volatility attributed to ruling in patent fight with Jazz Pharmaceuticals Mar 04 12:20am ET 5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024 Mar 01 5:39am ET Jazz Pharmaceuticals price target lowered to $230 from $235 at Barclays Mar 01 5:04am ET Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX) Mar 01 3:00am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Puma Biotechnology (PBYI) and MoonLake Immunotherapeutics (MLTX)

JAZZ Financials

1-year income & revenue

Key terms

JAZZ Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

JAZZ Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms